All news from Venereology

Bacterial Vaginosis: Better Communication between Patients and HCPs Highlighted

According to an online survey, although healthcare providers (HCPs) report sharing crucial information on bacterial vaginosis (BV) with patients, the associated risks of the condition remain a mystery to many women, indicating a significant disconnect. With BV known to be the most prevalent gynecologic infection in the U.S., affecting 21 million women each year, it's clear that further education is needed to bridge this gap in communication and help women to obtain diagnosis and treatment initiation sooner.

'Hibernating' HIV Strains: Novel way for Dating

Researchers at the BC Centre for Excellence in HIV/AIDS (BC-CfE) and Simon Fraser University (SFU), in partnership with University of British Columbia (UBC) and Western University, have developed a novel way for dating "hibernating" HIV strains, in an advancement for HIV cure research in the province.

Published in Proceedings of the National Academy of Sciences (PNAS), the BC-CfE's first major scientific contribution to the area of HIV cure research confirms that dormant HIV strains can persist in the body for decades.

Role of HIV RNA Expression Inhibitors in HIV-infected individuals

Immune activation and inflammation persist in the majority of treated HIV-infected individuals and is associated with excess risk of mortality and morbidity.

A new study suggests that use of HIV RNA expression inhibitors as adjunct therapy might diminish atypical inflammation and restore immune function in HIV-infected individuals on combination antiretroviral therapy (cART). These findings appear online in the journal Nature Communications.

More Insights on Drug-Resistance of Gonorrhea in the EU

Neisseria gonorrhoea continues to show high levels of resistance to azithromycin across the European Union and European Economic Area, according to the 2016 results of the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP).

This threatens the effectiveness of the currently recommended dual therapy regimen for gonorrhoea. Overall, the rates of resistance to cefixime, ceftriaxone and azithromycin have remained stable when compared to recent years.